OUR APPROACH

EVOQ Therapeutics is pioneering the development of a proprietary technology that represents a genuine breakthrough for autoimmune disease and cancer therapy.

Autoimmune Disease Vaccines

EVOQ's technology has demonstrated breakthrough efficacy in the gold-standard EAE model for Multiple Sclerosis (MS). Success with this preclinical model is considered proof of concept for the potential utility of a therapy in a wide range of autoimmune diseases.

With prevalence on the rise, Autoimmune diseases have a devastating impact on the lives of millions of children and adults around the world.

Examples include:

  • Type 1 Diabetes

  • Celiac disease

  • Multiple sclerosis

  • Neuromyelitis optica

  • Rheumatoid arthritis

  • Myasthenia gravis

  • Pemphigus

  • Graves' disease

EVOQ is now engaged in preclinical studies for a number of autoimmune diseases.
 

Cancer Vaccines

EVOQ has demonstrated that delivering antigens and adjuvants with our vaccine platform evokes an immune response that is 30 times more powerful than the best antigen adjuvant combinations.

Our vaccine produces robust anti-tumor immunity against new tumor epitopes (regardless of pre-existing immunity) while broadening T-cell responses against multiple tumor epitopes.

Furthermore, when used in combination with immune checkpoint inhibitors, our vaccine generates striking levels of anti-tumor immunity that eradicates established tumors and protects animals against tumor recurrence.

Preclinical efficacy has been demonstrated in multiple cancer types including: 

  • Colon Cancer

  • Melanoma

  • HPV-associated Lung

  • HPV-associated Head & Neck

  • KRAS-associated cancers

  • Glioblastoma multiforme

EVOQ's technology utilizes a proprietary synthetic HDL NanoDisc that has been optimized to deliver antigens (with or without adjuvants) to Dendritic cell depots located in lymph nodes.

EVOQ'S NanoDisc Vaccines have...

  • Produced superior T-cell responses through more effective targeting of the lymph-system. 

  • The versatility required for efficient delivery of wide range of peptides and adjuvants in a simple SC injection. It has been tested with Poly IC:LC, CpG, and a diverse set of more than 140 peptides to date.

  • An exceptionally clean safety profile - already tested in man

  • A well characterized manufacturing schema with 2+ years of stability